Lonza Group has appointed venture firm Prolog Ventures to manage a fund that will invest in consumer health technology developers.
Switzerland-headquartered biotechnology and chemicals supplier Lonza Group has formed a corporate venturing fund in partnership with US-based venture capital firm Prolog Ventures.
Prolog Lonza Consumer Fund will invest in North America-based consumer healthcare technology developers working on products that can improve or maintain the health of people and their pets or companion animals.
In particular, the fund will target areas such as personal and home care, medical food, dietary supplements, and functional food and beverages. It will be managed by…
